ArticleOncogene2006
Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 41 citations in OpenAlex.
- A2B5 Expression in Central Nervous System and Gliomas.International journal of molecular sciences · 2022Review
- Signaling domains of cancer-associated glycolipids.Glycoconjugate journal · 2022Review
- Identifying an Immune-Related Gene ST8SIA1 as a Novel Target in Patients With Clear-Cell Renal Cell Carcinoma.Frontiers in pharmacology · 2022Article
- Sphingolipid metabolism in the development and progression of cancer: one cancer's help is another's hindrance.Molecular oncology · 2021Review
- Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer.Annals of translational medicine · 2019Article
- Ganglioside GD3 synthase (GD3S), a novel cancer drug target.Acta pharmaceutica Sinica. B · 2018Review
- Sialylation: an Avenue to Target Cancer Cells.Pathology oncology research : POR · 2016Review
- Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.PloS one · 2016Article
- Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance.International journal of molecular sciences · 2014Review
- Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3.The Journal of biological chemistry · 2011Article
- Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer.Journal of cancer research and clinical oncology · 2009Article
- GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.Cancer research · 2009Article
- Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference.Pathology oncology research : POR · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gangliosides GD3 and GD2 are specifically expressed in neuro-ectoderm-derived tumors, and are considered to play roles in the malignant properties of those cells. We analysed effects of small interfering (si) RNAs against GD3 synthase gene on the expression of ganglioside GD2 and biological phenotypes of human lung cancer cells expressing GD2. An siRNA could suppress the mRNA level of GD3 synthase gene even by single transfection, whereas repeated transfection was required to suppress GD2 expression on the cell surface. Significant reduction in the cell growth and invasion activity was observed in both lung cancer cell lines examined, when repeatedly transfected with the siRNA twice a week. DNA ladder formation was observed after third transfection, indicating the potent induction of apoptosis. Stable transfection of an RNAi expression vector with H1 RNA promoter was also examined. Transfectant cells with the RNAi expression vector showed almost equivalent suppression of GD2 expression and tumor properties in vitro. Furthermore, the stable transfectant cells showed slower cell growth than the control cells in severe combined immunodeficiency mice. These results suggested that siRNAs and/or RNAi expression vectors to generate siRNAs are promising approach to overcome human lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.